Insurance Coverage and Processing Labelling White Paper 
Pharmaceutical Technology
NOVEMBER 30, 2022
weight reduction in obese individuals, as per its label. Furthermore, in order to make up for shortages Novo Nordisk’s Ozempic, a version of semaglutide that is approved to treat type 2 diabetes, was used off-label for obese patients. In the US, most private health insurers have been slow to cover the cost of anti-obesity therapeutics.
Pharmaceutical Technology
NOVEMBER 30, 2022
weight reduction in obese individuals, as per its label. Furthermore, in order to make up for shortages Novo Nordisk’s Ozempic, a version of semaglutide that is approved to treat type 2 diabetes, was used off-label for obese patients. In the US, most private health insurers have been slow to cover the cost of anti-obesity therapeutics.
Expert insights. Personalized for you.
105 
Let's personalize your content